TIMP-2 mutant decreases MMP-2 activity and augments pressure overload induced LV dysfunction and heart failure

Archives of Physiology and Biochemistry

Volumn 119, Issue 2, 2013, Pages 65-74

  Givvimani, S ^a   Kundu, S ^a   Narayanan, N ^a   Armaghan, F ^a   Qipshidze, N ^a   Pushpakumar, S ^a   Vacek, T P ^a   Tyagi, S C ^a  

^a University of Louisville School of Medicine   (United States)

Author keywords

Angiogenesis; Connexins; Heart failure; Matrix remodelling; Pressure overload; TIMP 2

Indexed keywords

ANGIOGENESIS INHIBITOR; CONNEXIN 37; CONNEXIN 43; GAP JUNCTION PROTEIN; GELATINASE A; TISSUE INHIBITOR OF METALLOPROTEINASE 2; VASCULOTROPIN A;

ANGIOGENESIS; ANIMAL; AORTA; ARTICLE; C57BL MOUSE; CARDIOMEGALY; EXTRACELLULAR MATRIX; GENE EXPRESSION; GENETICS; HEART FAILURE; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE; HEART VENTRICLE REMODELING; HYPERTENSION; KNOCKOUT MOUSE; LIGATION; MALE; MOUSE; PATHOPHYSIOLOGY; PHYSIOLOGY; SECRETION (PROCESS); ULTRASTRUCTURE;

ANGIOGENESIS INHIBITORS; ANIMALS; AORTA; CARDIOMEGALY; CONNEXIN 43; CONNEXINS; CONSTRICTION; EXTRACELLULAR MATRIX; GENE EXPRESSION; HEART FAILURE; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; MALE; MATRIX METALLOPROTEINASE 2; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MYOCARDIUM; NEOVASCULARIZATION, PHYSIOLOGIC; TISSUE INHIBITOR OF METALLOPROTEINASE-2; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR REMODELING;

MUS;

EID: 84877110116     PISSN: 13813455     EISSN: 17444160     Source Type: Journal    
DOI: 10.3109/13813455.2012.755548     Document Type: Article

References (30)

1. Alexander SM, Jackson KJ, Bushnell KM, McGuire PG. (1997). Spatial and temporal expression of the 72-kDa type IV collagenase (MMP-2) correlates with development and differentiation of valves in the embryonic avian heart. Dev Dyn, 209:261-8.
2. Braunwald E. (1980). Heart disease: A textbook of cardiovascular medicine. Philadelphia, PA: W.B. Saunders.
3. Brew K, Nagase H. (2010). The tissue inhibitors of metalloproteinases (TIMPs): An ancient family with structural and functional diversity. Biochim Biophys Acta, 1803:55-71.
4. Butler GS, Butler MJ, Atkinson SJ, et al. (1998). The TIMP2 membrane type 1 metalloproteinase "receptor" regulates the concentration and efficient activation of progelatinase A. A kinetic study. J Biol Chem, 273:871-80.
5. Ducharme A, Frantz S, Aikawa M, et al. (2000). Targeted deletion of matrix metalloproteinase-9 attenuates left ventricular enlargement and collagen accumulation after experimental myocardial infarction. J Clin Invest, 106:55-62.
6. Dupont E, Matsushita T, Kaba RA, et al. (2001). Altered connexin expression in human congestive heart failure. J Mol Cell Cardiol, 33:359-71.
7. Frey N, Olson EN. (2003). Cardiac hypertrophy: The good, the bad, and the ugly. Annu Rev Physiol, 65:45-79.
8. Givvimani S, Tyagi N, Sen U, et al. (2010). MMP-2/TIMP-2/TIMP-4 versus MMP-9/TIMP-3 in transition from compensatory hypertrophy and angiogenesis to decompensatory heart failure. Arch Physiol Biochem, 116:63-72.
9. Givvimani S, Munjal C, Gargoum R, et al. (2011a). Hydrogen sulfide mitigates transition from compensatory hypertrophy to heart failure. J Appl Physiol, 110:1093-100.
10. Givvimani S, Qipshidze N, Tyagi N, et al. (2011b). Synergism between arrhythmia and hyperhomo-cysteinemia in structural heart disease. Int J Physiol Pathophysiol Pharmacol, 3:107-19.
11. Givvimani S, Munjal C, Tyagi N, et al. (2012). Mitochondrial division/mitophagy inhibitor (Mdivi) ameliorates pressure overload induced heart failure. PLoS One, 7:e32388.
12. Heymans S, Schroen B, Vermeersch P, et al. (2005). Increased cardiac expression of tissue inhibitor of metalloproteinase-1 and tissue inhibitor of metalloproteinase-2 is related to cardiac fibrosis and dysfunction in the chronic pressure-overloaded human heart. Circulation, 112:1136-44.
13. Jansen JA, van Veen TA, de Jong S, et al. (2012). Reduced Cx43 expression triggers increased fibrosis due to enhanced fibroblast activity. Circ Arrhythm Electrophysiol, 5:380-90.
14. Johnson JL, Baker AH, Oka K, et al. (2006). Suppression of atherosclerotic plaque progression and instability by tissue inhibitor of metalloproteinase-2: Involvement of macrophage migration and apoptosis. Circulation, 113:2435-44.
15. Kandalam V, Basu R, Abraham T, et al. (2010). TIMP2 deficiency accelerates adverse post-myocardial infarction remodeling because of enhanced MT1-MMP activity despite lack of MMP2 activation. Circ Res, 106:796-808.
16. Kandalam V, Basu R, Moore L, et al. (2011). Lack of tissue inhibitor of metalloproteinases 2 leads to exacerbated left ventricular dysfunction and adverse extracellular matrix remodeling in response to biome-chanical stress. Circulation, 124:2094-105.
17. Kassiri Z, Khokha R. (2005). Myocardial extra-cellular matrix and its regulation by metalloproteinases and their inhibitors. Thromb Haemost, 93:212-19.
18. Nuttall RK, Sampieri CL, Pennington CJ, et al. (2004). Expression analysis of the entire MMP and TIMP gene families during mouse tissue development. FEBS Lett, 563:129-34.
19. Papaioannou VE, Fox JG. (1993). Efficacy of tribromoethanol anesthesia in mice. Lab Anim Sci, 43:189-92.
20. Ramani R, Nilles K, Gibson G, et al. (2011). Tissue inhibitor of metalloproteinase-2 gene delivery ameliorates postinfarction cardiac remodeling. Clin Transl Sci, 4:24-31.
21. Robbins JR, McGuire PG, Wehrle-Haller B, Rogers SL. (1999). Diminished matrix metalloproteinase 2 (MMP-2) in ectomesench-yme-derived tissues of the Patch mutant mouse: Regulation of MMP-2 by PDGF and effects on mesenchymal cell migration. Dev Biol, 212:255-63.
22. Rottman JN, Ni G, Brown M. (2007). Echocardiographic evaluation of ventricular function in mice. Echocardiography, 24:83-89.
23. Sato H, Kinoshita T, Takino T, et al. (1996). Activation of a recombinant membrane type 1-matrix metalloproteinase (MT1-MMP) by furin and its interaction with tissue inhibitor of metalloproteinases (TIMP)-2. FEBS Lett, 393:101-4.
24. Sen U, Sathnur PB, Kundu S, et al. (2012). Increased endogenous H2S generation by CBS, CSE and 3MST gene therapy improves ex vivo renovascular relaxation in hyperhomocysteinemia. Am J Physiol Cell Physiol, 303:C41-51.
25. Sodha NR, Clements RT, Boodhwani M, et al. (2009). Endostatin and angiostatin are increased in diabetic patients with coronary artery disease and associated with impaired coronary collateral formation. Am J Physiol Heart Circ Physiol, 296:H428-34.
26. Spinale FG. (2007). Myocardial matrix remodeling and the matrix metalloproteinases: Influence on cardiac form and function. Physiol Rev, 87:1285-342.
27. Strongin AY, Collier I, Bannikov G, et al. (1995). Mechanism of cell surface activation of 72-kDa type IV collagenase. Isolation of the activated form of the membrane metalloprotease. J Biol Chem, 270:5331-8.
28. Toischer K, Rokita AG, Unsold B, et al. (2010). Differential cardiac remodeling in preload versus afterload. Circulation, 122:993-1003.
29. Van Linthout S, Seeland U, Riad A, et al. (2008). Reduced MMP-2 activity contributes to cardiac fibrosis in experimental diabetic cardiomyopathy. Basic Res Cardiol, 103:319-27.
30. Wang Z, Juttermann R, Soloway PD. (2000). TIMP-2 is required for efficient activation of proMMP-2 in vivo. J Biol Chem, 275:26411-15.